These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 27066773

  • 1. Effect of serum anti-tumour necrosis factor (TNF) drug trough concentrations and antidrug antibodies (ADAb) to further anti-TNF short-term effectiveness after switching in rheumatoid arthritis and axial spondyloarthritis.
    Vincent FB, Pavy S, Krzysiek R, Lequerré T, Sellam J, Taoufik Y, Mariette X, Miceli-Richard C.
    Joint Bone Spine; 2016 Oct; 83(5):595-7. PubMed ID: 27066773
    [No Abstract] [Full Text] [Related]

  • 2. No Correlation between Anti-drug Antibodies and Therapeutic Response in Tunisian Patients with Chronic Inflammatory Diseases Treated by TNF Blockers.
    Bouden S, Laadhar L, Soua J, Ben Messaoud M, Rouached L, Ayadi I, Saidane O, Ben Tekaya A, Mahmoud I, Rekik S, Srairi HS, Tekaya R, Bellakhal S, Fekih M, Abdelmoula L, Kallel M.
    Curr Rheumatol Rev; 2024 Oct; 20(4):435-443. PubMed ID: 38314598
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Exploring TNFi drug-levels and anti-drug antibodies during tapering among patients with inflammatory arthritis: secondary analyses from the randomised BIODOPT trial.
    Uhrenholt L, Sørensen MER, Lauridsen KB, Duch K, Dreyer L, Christensen R, Hauge EM, Loft AG, Rasch MNB, Horn HC, Taylor PC, Nielsen KR, Kristensen S.
    Rheumatol Int; 2024 Oct; 44(10):1897-1908. PubMed ID: 39043980
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Personalized medicine in rheumatoid arthritis: How immunogenicity impacts use of TNF inhibitors.
    Bodio C, Grossi C, Pregnolato F, Favalli EG, Biggioggero M, Marchesoni A, Murgo A, Filippini M, Migliorini P, Caporali R, Pellerito R, Ciccia F, Sarzi-Puttini P, Perosa F, Paolazzi G, Hollan I, Bendtzen K, Meroni PL, Borghi MO.
    Autoimmun Rev; 2020 May; 19(5):102509. PubMed ID: 32173513
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Persistence of Infliximab in Circulation for 7 Years?
    Kelting SM, Kimpel DL, Bruns DE.
    Clin Chem; 2015 Nov; 61(11):1420-1. PubMed ID: 26511353
    [No Abstract] [Full Text] [Related]

  • 18. Retention rates of adalimumab, etanercept and infliximab as first-line biotherapy agent for rheumatoid arthritis patients in daily practice - Auvergne experience.
    Soubrier M, Pereira B, Frayssac T, Fan A, Couderc M, Malochet-Guinamand S, Mathieu S, Tatar Z, Tournadre A, Dubost JJ.
    Int J Rheum Dis; 2018 Nov; 21(11):1924-1932. PubMed ID: 28901727
    [Abstract] [Full Text] [Related]

  • 19. High BMI is associated with lower TNF-α inhibitor serum trough levels and higher disease activity in patients with axial spondyloarthritis.
    de Wolff L, Arends S, Brouwer E, Bootsma H, Spoorenberg A.
    Arthritis Res Ther; 2023 Oct 17; 25(1):202. PubMed ID: 37848964
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.